Table 1.
Mean and SD of patients’ demographic and clinical baseline characteristics and their correlations with CDSS total scores at baseline (n = 198) and 12-month follow-up (n = 127)
| Mean (SD) | Correlation With CDSS total score at baseline (Pearson) | Correlation with CDSS total score at12-month follow-up (Pearson) | |
|---|---|---|---|
| Age |
27.98 (8.70) |
0.01 |
0.10 |
| Gender (M) |
N = 127 (64%) |
0.18* |
0.13 |
| Education (year) |
12.71 (2.93) |
−0.02 |
−0.13 |
| GAF symptom |
41.12 (11.38) |
−0.29** |
−0.26** |
| GAF function |
44.14 (12.65) |
−0.11 |
−0.22* |
| PANSS positive |
12.95 (4.49) |
0.07 |
0.06 |
| PANSS negative |
20.13 (7.72) |
0.11 |
0.18* |
| PANSS excitative |
8.07 (2.84) |
0.21* |
−0.04 |
| PANSS depressive |
12.15 (3.61) |
0.58** |
0.37** |
| PANSS cognitive |
5.38 (2.07) |
−0.004 |
0.06 |
| PANSS-total score |
63.38 (15.00) |
0.27** |
0.23* |
| PAS childhood social |
2.51 (3.05) |
0.26** |
0.32** |
| PAS childhood academic |
3.45 (2.43) |
0.26** |
0.26** |
| PAS early adolescence social |
2.69 (2.88) |
0.21** |
0.22* |
| PAS early adolesc. academic |
4.26 (2.75) |
0.24* |
0.17 |
| DUPln |
1.63 (0.80) |
0.23** |
0.30** |
| Insight (PANSS G12) |
2.76 (1.36) |
−0.18* |
−0.11 |
| AUDIT |
7.76 (7.70) |
0.17* |
0.09 |
| DUDIT |
6.36 (9.58) |
0.10 |
0.03 |
| Anti-depressive medication day dosis |
37.50 (35.75) |
0.05 |
0.03 |
| Anti-psychotic medication, day dosis |
97.17 (155.88) |
−0.05 |
−0.07 |
| CDSS total baseline | 6.23 (4.44) | -------------------- | 0.48** |
*Correlation is significant at the 0.05 level (2-tailed).
**Correlation is significant at the 0.01 level (2-tailed).
PANSS Positive and negative syndrome scale.
GAF Global assessment of functioning.
PAS Premorbid adjustment scale.
DUP Duration of untreated psychosis.
AUDIT Alcohol use disorders identification test.
DUDIT Drug use disorders identification test.
CDSS Calgary depression scale for schizophrenia.